Decoding Breast Cancer: How Blood Counts Can Predict Treatment Success
"New research reveals that simple blood tests, focusing on eosinophil levels, could predict how triple-negative and HER2-positive breast cancers respond to neoadjuvant chemotherapy, offering hope for more personalized cancer treatments."
In the ongoing battle against breast cancer, which affects millions globally, researchers are constantly seeking ways to refine treatment strategies. Neoadjuvant chemotherapy, given before surgery, is a common approach, yet predicting its success remains a challenge. Now, a recent study sheds light on the potential of simple blood tests to forecast how well certain breast cancers respond to this treatment.
Published in 'Oncotarget' in 2018, the research explores the role of eosinophils—a type of white blood cell—in predicting the effectiveness of neoadjuvant chemotherapy in patients with triple-negative and hormone receptor-negative/HER2-positive breast cancers. These cancers are known for their aggressive nature and the urgent need for effective, targeted therapies.
The study suggests that by monitoring eosinophil and lymphocyte counts, doctors may gain valuable insights into which patients are most likely to benefit from chemotherapy, potentially paving the way for more personalized and effective cancer care.
Cost Barriers and Personalized Care
Cost is a major barrier in breast cancer care: a 2026 ZipDo research report finds that 62% of U.S. breast cancer patients without health insurance delay or forgo treatment due to cost, compared with 8% of those with private insurance. Beyond access, treatment is highly individualized. As Verywell Health notes, metastatic breast cancers are not all treated the same, and the diagnosis incorporates tumor location, tumor grade, tumor size, hormone receptor status, and HER2 status, each of which directs the course of treatment. For those who complete treatment, follow-up includes managing late and long-term side effects and watching for a new cancer, a focus of the American Cancer Society's patient resources.
A Tailored Toolkit of Standard Treatments
Treatment for breast cancer is tailored to the type and stage of the disease and may include surgery, radiation, chemotherapy, hormone therapy, targeted drug therapy, or immunotherapy, according to Verywell Health. The goal is either to cure the cancer or to prolong survival while preserving a high quality of life. In stage III disease, the American Cancer Society notes, the tumor is more than 5 cm across, or is growing into the skin or underlying muscle, or the cancer has spread to many nearby lymph nodes, and two main treatment approaches are typically considered. Screening also plays a role in catching disease earlier, with options including self-exams, mammograms, ultrasounds, and MRIs.
A Field Forged Over Decades
The treatment of cancer has evolved considerably over time, with approaches now varying by cancer type — breast, lung, or colorectal, for example — according to Liv Hospital's historical overview. For breast cancer specifically, that evolution has produced a spectrum of surgical, radiation, and systemic options. Institutions such as Memorial Sloan Kettering Cancer Center emphasize that where a patient gets treated first matters, underscoring the importance of specialized, early care. Together, these sources point to a field shaped by decades of refinement toward more targeted, individualized treatment.
Unlocking Clues from Blood Cells: Eosinophils and Lymphocytes
The study, led by Concetta Elisa Onesti and colleagues, retrospectively analyzed data from 112 breast cancer patients treated with standard neoadjuvant chemotherapy. The focus was on patients with triple-negative breast cancer (TNBC) and hormone receptor-negative/HER2-positive cancer, two subtypes that often require aggressive treatment approaches.
- Higher eosinophil counts at baseline were linked to a higher rate of pathological complete response.
- Elevated eosinophil and lymphocyte counts correlated with improved breast cancer-specific survival rates.
- Combining eosinophil and lymphocyte data into a single metric further enhanced the ability to predict treatment response and survival outcomes.
Precision Medicine and Recurrence Awareness
Breast cancer is common, making up roughly 32 percent of new cancer diagnoses in women, according to Everyday Health. Current research emphasizes precision medicine, with Life Extension's treatment protocol describing how therapies can be tailored to a patient's unique characteristics and preferences. Even after successful initial treatment, the disease can return: Everyday Health notes that recurrent breast cancer may appear months or years after initial treatment, which shapes long-term surveillance and planning.
Debated Screens, Rare Cases, and Pregnancy Dilemmas
Treatment decisions are complicated by real-world failures and edge cases. One report claims that over 30 percent of breast cancer cases are misdiagnosed, causing unnecessary treatment, and argues that Swedish breast cancer mortality statistics are consistent with studies showing limited or no impact of screening on mortality — a claim that reflects ongoing debate over screening's value. Male breast cancer adds another layer of complexity, since it can arise from inherited gene mutations and a family history of the disease. For women diagnosed during pregnancy, Cancer Australia notes that breast surgery is possible with only a slight risk of miscarriage, and that risk is lower after the first trimester.
Conventional Care at the Core
When comparing treatment approaches, the choice is especially critical for aggressive subtypes such as triple-negative breast cancer (TNBC). As one comparison explains, conventional approaches such as chemotherapy focus on targeting and eliminating cancer cells through rigorous medical protocols. This framing highlights why conventional treatment remains the backbone of care for high-risk disease, even as newer therapies continue to be explored.
A Promising Horizon for Personalized Cancer Treatment
While these findings offer a promising step toward personalized cancer treatment, the researchers emphasize the need for larger studies to confirm these results and to fully understand the underlying mechanisms. The potential to use simple, affordable blood tests to guide treatment decisions could significantly improve outcomes for patients with aggressive forms of breast cancer, marking a significant stride in the ongoing quest for more effective and personalized cancer care.
Multidisciplinary, Individualized Decisions
Expert consensus guidelines emphasize that some of the most complex decisions — such as treating breast cancer during pregnancy — should be made on an individual basis. The ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3) recommend that such treatment be decided according to international guidelines within an expert multidisciplinary team, expanded to include obstetricians and perinatologists. This reflects a broader principle in modern breast cancer care: treatment plans should be personalized and guided by multidisciplinary expertise rather than one-size-fits-all protocols.
Next-Generation Therapies on the Horizon
Despite major progress, unmet needs persist in optimizing HER2-targeted treatment sequences and addressing resistance mechanisms, according to an OncLive expert panel. Next-generation antibody-drug conjugates and bispecific antibodies are among the approaches under exploration. For HER2-negative disease, ongoing trials are expected to bring new regimens combining immunotherapies, targeted therapies, and chemotherapy combinations into the market in the near future. At the earliest end of the spectrum, stage 0 breast cancer can be very slow-growing and may never progress to invasive cancer, and it can be successfully treated.
Global Burden and Unequal Access
Breast cancer remains the leading cause of cancer-related deaths among women globally, with an estimated 2.3 million new cases and approximately 685,000 deaths reported worldwide in 2020, and case numbers have been rising steadily in sub-Saharan Africa. Most breast lumps and changes, however, are not cancer — the majority are benign conditions. Systemic challenges also affect who receives care: research on the top five causes of cancer death in the United States found that neighborhood-level social vulnerability has an impact on clinical trial enrollment. Personal experience can also drive progress — one researcher switched his doctoral work to breast cancer treatment after his wife died of the disease.
Predicting Outcomes, Personalizing Hope
New tools aim to predict how well a patient will respond to treatment before it begins. Lab-grown mini tumors derived from patient tissue are helping scientists predict breast cancer treatment success, an advance that could hasten more personalized treatment — including for triple-negative breast cancer, which is especially aggressive and hard to treat. Separately, researchers at UT Austin's ICES institute report that their mathematical model for predicting breast cancer treatment responses has now been validated for generalizability in the multi-institutional I-SPY2 cohort, growing evidence that such models can make a real-world impact in breast cancer care.